Q3 2025 Lineage Cell Therapeutics Inc Earnings Call Transcript

Nov 6, 2025 / 09:30 PM GMT

Release Date Price: €1.54 (+0.65%)

Transcript 10-Q8-K

Key Points

Positve

Lineage Cell Therapeutics Inc (LCTX) has expanded its clinical trial sites for the Opergen program, with 15 unique locations now open, indicating positive momentum.
The partnership with William DuMont Investor (WDI) is expected to fund up to $12 million for the development of a new cell transplant program for hearing loss, showcasing the company's ability to secure external funding.
The company has a strong cash position of $40.5 million, which is expected to support operations into Q2 of 2027, providing financial stability.
Lineage Cell Therapeutics Inc (LCTX) is exploring new cell types for potential development, indicating a proactive approach to expanding its pipeline.
The company is leveraging its unique manufacturing capabilities to address production scale challenges in cell therapy, particularly for type 1 diabetes, which could open new market opportunities.

Negative

Lineage Cell Therapeutics Inc (LCTX) reported a net loss of $29.8 million for the third quarter, significantly higher than the $3 million loss in the same period in 2024, primarily due to warrant liabilities.
The company's revenue decreased slightly to $3.7 million from $3.8 million in the same period last year, driven by lower royalty and service revenues.
There is uncertainty regarding the receipt of a SERM grant, which could impact funding for the OPC-1 spinal cord injury study.
The company does not have full visibility into the enrollment or findings of the Gillette study, which could affect strategic planning.
The potential for delays in advancing the Opergen program into a controlled clinical trial, as the decision rests with partners Roche and Genentech.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LCTX.A - Lineage Cell Therapeutics Inc
Q3 2025 Lineage Cell Therapeutics Inc Earnings Call
Nov 06, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Line A Cell Therapeutics 3rd quarter 2025 conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the investor section of Lineage's website at www. Lineageal.com. This call is subject to copyright. And is the property of lineage, and the recordings, reproductions, or transmissions of this call without the express written consent of lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Iona Hoh, head of investor relations of Line Age. Miss Hong, please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.